MaxCyte Inc - Asset Resilience Ratio
MaxCyte Inc (MXCT) has an Asset Resilience Ratio of 43.45% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does MaxCyte Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how MaxCyte Inc's Asset Resilience Ratio has changed over time. See MXCT book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down MaxCyte Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MaxCyte Inc (MXCT) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $92.75 Million | 43.45% |
| Total Liquid Assets | $92.75 Million | 43.45% |
Asset Resilience Insights
- Very High Liquidity: MaxCyte Inc maintains exceptional liquid asset reserves at 43.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MaxCyte Inc Industry Peers by Asset Resilience Ratio
Compare MaxCyte Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 3.37% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS |
Medical Devices | 54.67% |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO |
Medical Devices | 30.97% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
|
Aligned Genetics Inc
KQ:238120 |
Medical Devices | 2.22% |
|
Heramed Ltd
AU:HMD |
Medical Devices | 0.83% |
|
Acarix A/S
ST:ACARIX |
Medical Devices | 37.81% |
Annual Asset Resilience Ratio for MaxCyte Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for MaxCyte Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 52.87% | $126.60 Million | $239.47 Million | +7.47pp |
| 2023-12-31 | 45.39% | $121.78 Million | $268.27 Million | -30.05pp |
| 2022-12-31 | 75.45% | $216.28 Million | $286.65 Million | +2.50pp |
| 2021-12-31 | 72.95% | $207.26 Million | $284.12 Million | +42.03pp |
| 2020-12-31 | 30.91% | $16.01 Million | $51.78 Million | +25.92pp |
| 2019-12-31 | 5.00% | $1.50 Million | $29.99 Million | -8.15pp |
| 2018-12-31 | 13.15% | $3.19 Million | $24.27 Million | -- |
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based … Read more